P1(A) polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement

Journal of the American College of Cardiology

Volumn 36, Issue 1, 2000, Pages 84-89

  Kastrati, Adnan ^a   Koch, Werner ^a   Gawaz, Meinrad ^a   Mehilli, Julinda ^a   Böttiger, Corinna ^a   Schömig, Kathrin ^a   Von Beckerath, Nicolas ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IIIA; THROMBOCYTE ANTIGEN; 1A ALLOANTIGEN, HUMAN; BETA3 INTEGRIN; DNA; EPITOPE; FIBRINOGEN RECEPTOR; HUMAN PLATELET ANTIGEN 1B; INTEGRIN; LEUKOCYTE ANTIGEN; PRIMER DNA;

ADULT; AGED; ALLELE; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DEATH; ENZYME ANALYSIS; FEMALE; GENOTYPE; HEART INFARCTION; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN POLYMORPHISM; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; ANGIOCARDIOGRAPHY; BLOOD; CHEMISTRY; COMPARATIVE STUDY; CORONARY ARTERY THROMBOSIS; GENETIC MARKER; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RADIOGRAPHY; RISK; STENT;

AGED; ALLELES; ANGINA PECTORIS; ANTIGENS, CD; ANTIGENS, HUMAN PLATELET; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DNA; DNA PRIMERS; EPITOPES; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; INTEGRIN BETA3; INTEGRINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET MEMBRANE GLYCOPROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STENTS;

EID: 0033624079     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00709-9     Document Type: Article

References (37)

1. Narins C.R., Topol E.J. Attention shifts to the white clot. Lancet. 350:(Suppl III):1997;2.
2. Handin R.I. Platelets and coronary artery disease. N Engl J Med. 334:1996;1126-1127.
3. Wu K.K. Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med. 239:1996;17-34.
4. Report of a meeting of Physicians and Scientists, University of Texas Health Science Center at Houston and Texas Heart Institute, Houston. Lancet. 344:1994;991-995.
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk angioplasty. N Engl J Med. 330:1994;956-961.
6. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
7. Kereiakes D.J., Lincoff A.M., Miller D.P., et al. Abciximab therapy and unplanned coronary stent deployment favorable effects on stent use, clinical outcomes and bleeding complications. EPILOG Trial Investigators . Circulation. 97:1998;857-864.
8. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
9. 3, the fibrinogen receptor. Proc Soc Exp Biol Med. 208:1995;346-360.
10. Weiss E.J., Bray P.F., Tayback M., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 334:1996;1090-1094.
11. A polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation. 96:1997;1424-1431.
12. Gardemann A., Humme J., Stricker J., et al. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb Haemost. 80:1998;214-217.
13. Garcia-Ribes M., Gonzalez-Lamuno D., Hernandez-Estefania R., et al. Polymorphism of the platelet glycoprotein IIIa gene in patients with coronary stenosis. Thromb Haemost. 79:1998;1126-1129.
14. A1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke and venous thrombosis. Lancet. 349:1997;385-388.
15. Samani N.J., Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res. 33:1997;693-697.
16. Hato T., Minamoto Y., Fukuyama T., Fujita S. Polymorphisms of HPA-1 through 6 on platelet membrane glycoprotein receptors are not a genetic risk factor for myocardial infarction in the Japanese population. Am J Cardiol. 80:1997;1222-1224.
17. Durante-Mangoni E., Davies G.J., Ahmed N., et al. Coronary thrombosis and the platelet glycoprotein IIIA gene PLA2 polymorphism. Thromb Haemost. 80:1998;218-219.
18. Corral J., Gonzalez-Conejero R., Rivera J., et al. HPA-1 genotype in arterial thrombosis - role of HPA-1b polymorphism in platelet function. Blood Coagul Fibrinol. 8:1997;284-290.
19. Feng D., Lindpaintner K., Larson M.G., et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism the Framingham Offspring Study . Arterioscler Thromb Vasc Biol. 19:1999;1142-1147.
20. Goodall A.H., Curzen N., Panesar M., et al. Increased binding of fibrinogen to glycoprotein IIIa-Proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J. 20:1998;742-747.
21. A polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation. 99:1999;1005-1010.
22. Gawaz M., Neumann F.J., Ott I., et al. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart. 76:1996;166-172.
23. Nurden A.T. Platelet glycoprotein IIIa polymorphism and coronary thrombosis. Lancet. 350:1997;1189-1190.
24. Walter D.H., Schächinger V., Elsner M., et al. Platelet glycoprotein IIIa polymorphisms and risk of coronary stent thrombosis. Lancet. 350:1997;1217-1219.
25. Laule M., Cascorbi I., Stangl V., et al. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions a case-controlled study . Lancet. 353:1999;708-712.
26. Schömig A., Kastrati A., Mudra H., et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation. 90:1994;2716-2724.
27. Jin Y., Dietz H.C., Nurden A., Bray P.F. Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood. 82:1993;2281-2288.
28. A), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol. 89:1995;169-176.
29. Legler T.J., Kohler M., Mayr W.R., et al. Genotyping of the human platelet antigen systems 1 through 5 by multiplex polymerase chain reaction and ligation-based typing. Transfusion. 36:1996;426-431.
30. Ellis S.G., Vandormael M.G., Cowley M.J., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease implications for patient selection . Circulation. 82:1990;1193-1202.
31. Schühlen H., Kastrati A., Dirschinger J., et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 98:1998;104-111.
32. The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med. 312:1985;932-936.
33. Strachan T., Read A.P. Human Molecular Genetics. 1996;John Wiley & Sons, New York.
34. Nurden A.T. Polymorphisms of human platelet membrane glycoproteins structure and clinical significance . Thromb Haemost. 74:1995;345-351.
35. Neumann F.J., Gawaz M., Ott I., et al. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 27:1996;15-21.
36. Schömig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 334:1996;1084-1089.
37. A2 polymorphism and efficacy of aspirin (letter). Lancet. 351:1998;1253.